Moomoo AI 已提取核心信息
On February 2, 2024, NexImmune, Inc., a biotechnology company listed on Nasdaq under the ticker NEXI, announced a registered direct offering and a concurrent private placement expected to raise approximately $3.67 million. The offering, priced at-the-market under Nasdaq rules, involves the sale of 117,000 shares of common stock at $12.05 per share and pre-funded warrants exercisable for up to 187,731 shares at $12.049 per warrant. Additionally, unregistered warrants to purchase up to 304,731 shares of common stock at $12.05 per share are being offered in the private placement. The closing of the offerings is anticipated on February 6, 2024, subject to customary conditions. The company has agreed to certain restrictions on stock issuance for 20 days post-closing. H.C. Wainwright & Co. is acting as the exclusive placement agent...Show More
On February 2, 2024, NexImmune, Inc., a biotechnology company listed on Nasdaq under the ticker NEXI, announced a registered direct offering and a concurrent private placement expected to raise approximately $3.67 million. The offering, priced at-the-market under Nasdaq rules, involves the sale of 117,000 shares of common stock at $12.05 per share and pre-funded warrants exercisable for up to 187,731 shares at $12.049 per warrant. Additionally, unregistered warrants to purchase up to 304,731 shares of common stock at $12.05 per share are being offered in the private placement. The closing of the offerings is anticipated on February 6, 2024, subject to customary conditions. The company has agreed to certain restrictions on stock issuance for 20 days post-closing. H.C. Wainwright & Co. is acting as the exclusive placement agent, receiving a cash fee and warrants as compensation. The proceeds are intended for financing, business development, collaboration opportunities, working capital, and general corporate purposes. This announcement has led to the postponement of a special meeting of stockholders initially set for February 7, 2024, which was to vote on the company's liquidation and dissolution.
2024年2月2日，在纳斯达克上市的股票代码为NEXI的生物技术公司NexImmune, Inc. 宣布注册直接发行，并同时进行私募配售，预计将筹集约367万美元。此次发行根据纳斯达克规则在市场上定价，涉及以每股12.05美元的价格出售11.7万股普通股，以及以每份认股权证12.049美元的价格行使最多187,731股的预筹认股权证。此外，还通过私募发行了未注册的认股权证，以每股12.05美元的价格购买多达304,731股普通股。此次发行预计将于2024年2月6日结束，但须遵守惯例条件。该公司已同意在收盘后20天内对股票发行实行某些限制。H.C. Wainwright & Co. 担任独家配售代理，收取现金费和认股权证作为补偿。所得款项用于融资、业务发展、合作机会、营运资金和一般公司用途。该公告导致原定于2024年2月7日举行的股东特别会议推迟，该会议将对公司的清算和解散进行投票。
2024年2月2日，在纳斯达克上市的股票代码为NEXI的生物技术公司NexImmune, Inc. 宣布注册直接发行，并同时进行私募配售，预计将筹集约367万美元。此次发行根据纳斯达克规则在市场上定价，涉及以每股12.05美元的价格出售11.7万股普通股，以及以每份认股权证12.049美元的价格行使最多187,731股的预筹认股权证。此外，还通过私募发行了未注册的认股权证，以每股12.05美元的价格购买多达304,731股普通股。此次发行预计将于2024年2月6日结束，但须遵守惯例条件。该公司已同意在收盘后20天内对股票发行实行某些限制。H.C. Wainwright & Co. 担任独家配售代理，收取现金费和认股权证作为补偿。所得款项用于融资、业务发展、合作机会、营运资金和一般公司用途。该公告导致原定于2024年2月7日举行的股东特别会议推迟，该会议将对公司的清算和解散进行投票。
有用
没用
